depression
The company sees a clearer path to clinical validation and reimbursement through molecules that more directly measure how drugs affect the brain.
Genetika+ Snags CE Mark for Major Depressive Disorder Drug-Matching Test
The NeuroKaire test predicts a patient's drug response by combining patient-reported information, pharmacogenetics data, and so-called "brain-in-a-dish" functional testing.
The company wants to commercialize its first antidepressant-matching service in 2023 and is hoping to launch it as an LDT in the US.
Startup Circular Genomics Raises $4.5M in Seed Funding
The company was founded earlier this year to commercialize a test for depression based on circular RNA biomarker technology.
Pharmacogenomics Firm Genetika+ Raises $10M in Series A Round
The company is developing a test to predict the best antidepressant drug or drug combination for a specific patient.
May 10, 2018
Sep 15, 2017
Aug 11, 2016